Center for Policy Research
Working Paper
Health, Medical Innovation and Disability Insurance: A Case Study of HIV Antiretroviral Therapy
Perry Singleton
C.P.R. Working Paper No. 182
August 2015
Abstract
This study examines the effect of health on SSDI outcomes. The effect is identified by a new antiretroviral therapy to treat the human immunodeficiency virus. Administrative data on SSDI applications come from the Disability Research File. According to the analysis, the new therapy had an immediate and persistent effect on program entry. By 1997, the therapy decreased applications by 35.2 percent and new awards by 36.7 percent. Among existing beneficiaries, the therapy decreased program exits through death, but did not substantially increase program exits for work. By 1999, the therapy increased HIV-related expenditures by $43.6 million.
Related News
Research
Apr 12, 2024
Research
Oct 9, 2023
Commentary
Jan 11, 2023